The PE Ratio as of December 2024 (TTM) for Talaris Therapeutics, Inc. (TALS) is -1.56

According to Talaris Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.56. This represents a change of -124.31% compared to the average of 6.43 of the last 4 quarters.

Talaris Therapeutics, Inc. (TALS) Historical PE Ratio (quarterly & annually)

How has TALS PE Ratio performed in the past?

The mean historical PE Ratio of Talaris Therapeutics, Inc. over the last ten years is -367884.39. The current -1.56 PE Ratio has changed -99.96% with respect to the historical average. Over the past ten years (40 quarters), TALS's PE Ratio was at its highest in in the December 2023 quarter at 49.27. The PE Ratio was at its lowest in in the March 2022 quarter at -1013352.27.

Talaris Therapeutics, Inc. (TALS) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Talaris Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Talaris Therapeutics, Inc. (TALS) Average PE Ratio

How has TALS PE Ratio performed in the past?

The current PE Ratio of Talaris Therapeutics, Inc. (TALS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Talaris Therapeutics, Inc. (TALS) PE Ratio vs. Peers

How is TALS’s PE Ratio compared to its peers?

Talaris Therapeutics, Inc.’s PE Ratio is greater than Edgewise Therapeutics, Inc. (-22.36), less than Adicet Bio, Inc. (-0.71), greater than Cullinan Oncology, Inc. (-4.99), less than Vor Biopharma Inc. (-0.53), less than CytomX Therapeutics, Inc. (6.58), greater than Instil Bio, Inc. (-1.89), greater than Neoleukin Therapeutics, Inc. (-5.86), less than Spero Therapeutics, Inc. (17.30), greater than Assembly Biosciences, Inc. (-2.29), less than Nuvation Bio Inc. (-1.45), less than Achilles Therapeutics plc (-0.69), less than NextCure, Inc. (-0.41), greater than Ovid Therapeutics Inc. (-2.11), less than Connect Biopharma Holdings Limited (7.21),

Build a custom stock screener for Talaris Therapeutics, Inc. (TALS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Talaris Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Talaris Therapeutics, Inc. (TALS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Talaris Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.